Prostate-specific antigen response after short-term hormone therapy plus external-beam radiotherapy and outcome in patients treated on Radiation Therapy Oncology Group study 9413

Cancer

Volumn 119, Issue 11, 2013, Pages 1999-2004

  Cury, Fabio L ^a   Hunt, Daniel ^b   Roach III, MacK ^c   Shipley, William ^d   Gore, Elizabeth ^e   Hsu, I Chow ^c   Krisch, Robert E ^f   Seider, Michael J ^g   Sandler, Howard ^h   Lawton, Colleen ^e  

^a MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^b RADIATION THERAPY ONCOLOGY GROUP   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

^e MEDICAL COLLEGE OF WISCONSIN   (United States)

^f HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^g AKRON CITY HOSPITAL   (United States)

^h CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

androgen deprivation therapy; prediction of outcomes; prostate cancer; prostate specific antigen; radiation therapy

Indexed keywords

FLUTAMIDE; GONADORELIN AGONIST; PROSTATE SPECIFIC ANTIGEN; TESTOSTERONE;

ADULT; AGE; AGED; ARTICLE; CANCER HORMONE THERAPY; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE FREE SURVIVAL; DISEASE SPECIFIC SURVIVAL; EXTERNAL BEAM RADIOTHERAPY; FOLLOW UP; GLEASON SCORE; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; METASTASIS; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CANCER; TREATMENT FAILURE; TREATMENT RESPONSE;

AGED; AGED, 80 AND OVER; ANDROGEN ANTAGONISTS; DISEASE-FREE SURVIVAL; GONADOTROPIN-RELEASING HORMONE; HUMANS; MALE; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RADIOTHERAPY DOSAGE; RADIOTHERAPY, ADJUVANT; TREATMENT OUTCOME;

EID: 84878016620     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.28019     Document Type: Article

References (23)

1. Dal Pra A, Cury FL, Souhami L,. Combining radiation therapy and androgen deprivation for localized prostate cancer-a critical review. Curr Oncol. 2010; 17: 28-38.
2. Higano CS,. Side effects of androgen deprivation therapy: monitoring and minimizing toxicity. Urology. 2003; 61: 32-38.
3. O'Brien MF, Cronin AM, Fearn PA, et al. Pretreatment prostate-specific antigen (PSA) velocity and doubling time are associated with outcome but neither improves prediction of outcome beyond pretreatment PSA alone in patients treated with radical prostatectomy. J Clin Oncol. 2009; 27: 3591-3597.
4. Palma D, Tyldesley S, Blood P, et al. Pretreatment PSA velocity as a predictor of disease outcome following radical radiation therapy. Int J Radiat Oncol Biol Phys. 2007; 67: 1425-1429.
5. Roach M, 3rd, DeSilvio M, Lawton C, et al. Phase III trial comparing whole-pelvic versus prostate-only radiotherapy and neoadjuvant versus adjuvant combined androgen suppression: Radiation Therapy Oncology Group 9413. J Clin Oncol. 2003; 21: 1904-1911.
6. Roach M 3rd,. A Phase III Trial Comparing Whole Pelvic Irradiation Followed by a Conedown Boost to Boost Irradiation Only and Comparing Neoadjuvant to Adjuvant Total Androgen Suppression (TAS). Philadelphia, PA: Radiation Therapy Oncology Group; 1998.
7. Roach M 3rd, Hanks G, Thames H Jr, et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys. 2006; 65: 965-974.
8. Kaplan EL, Meier P,. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958; 53: 457-481.
9. Gaynor JJ, Feuer EJ, Tan CC, et al. On the use of cause-specific and conditional failure probabilities. J Am Stat Assoc. 1993; 88: 400-409.
10. Gray RJ,. A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat. 1988; 16: 1141-1154.
11. Cox DR,. Regression models and life tables. J R Stat Soc B. 1972; 34: 187-202.
12. Roach M 3rd, Bae K, Speight J, et al. Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: long-term results of RTOG 8610. J Clin Oncol. 2008; 26: 585-591.
13. D'Amico AV, Manola J, Loffredo M, et al. Six-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial. JAMA. 2004; 292: 821-827.
14. Hanks GE, Pajak TF, Porter A, et al. Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: the Radiation Therapy Oncology Group Protocol 92-02. J Clin Oncol. 2003; 21: 3972-3978.
15. Bolla M, Van Tienhoven G, Warde P, et al. External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study. Lancet Oncol. 2010; 11: 1066-1073.
16. Kuban DA, Levy LB, Cheung MR, et al. Long-term failure patterns and survival in a randomized dose-escalation trial for prostate cancer. Who dies of disease? Int J Radiat Oncol Biol Phys. 2011; 79: 1310-1317.
17. D'Amico AV, McLeod DG, Carroll PR, et al. Time to an undetectable prostate-specific antigen (PSA) after androgen suppression therapy for postoperative or postradiation PSA recurrence and prostate cancer-specific mortality. Cancer. 2007; 109: 1290-1295.
18. Ogawa K, Nakamura K, Sasaki T, et al. Postoperative radiotherapy for localized prostate cancer: clinical significance of nadir prostate-specific antigen value within 12 months. Anticancer Res. 2009; 29: 4605-4613.
19. Nickers P, Albert A, Waltregny D, et al. Prognostic value of PSA nadir ≤4 ng/mL within 4 months of high-dose radiotherapy for locally advanced prostate cancer. Int J Radiat Oncol Biol Phys. 2006; 65: 73-77.
20. Miller N, Smolkin ME, Bissonette E, et al. Undetectable prostate specific antigen at 6-12 months: a new marker for early success in hormonally treated patients after prostate brachytherapy. Cancer. 2005; 103: 2499-2506.
21. Crook J, Ludgate C, Malone S, et al. Report of a multicenter Canadian phase III randomized trial of 3 months vs. 8 months neoadjuvant androgen deprivation before standard-dose radiotherapy for clinically localized prostate cancer. Int J Radiat Oncol Biol Phys. 2004; 60: 15-23.
22. Alexander A, Crook J, Jones S, et al. Is biochemical response more important than duration of neoadjuvant hormone therapy before radiotherapy for clinically localized prostate cancer? An analysis of the 3- versus 8-month randomized trial. Int J Radiat Oncol Biol Phys. 2010; 76: 23-30.
23. D'Amico AV, Chen MH, de Castro M, et al. Surrogate endpoints for prostate cancer-specific mortality after radiotherapy and androgen suppression therapy in men with localised or locally advanced prostate cancer: an analysis of 2 randomised trials. Lancet Oncol. 2012; 13: 189-195.